340 related articles for article (PubMed ID: 33732239)
1. Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces.
Dopler A; Stibitzky S; Hevey R; Mannes M; Guariento M; Höchsmann B; Schrezenmeier H; Ricklin D; Schmidt CQ
Front Immunol; 2021; 12():615748. PubMed ID: 33732239
[TBL] [Abstract][Full Text] [Related]
2. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.
Hyvärinen S; Meri S; Jokiranta TS
Blood; 2016 Jun; 127(22):2701-10. PubMed ID: 27006390
[TBL] [Abstract][Full Text] [Related]
3. Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases.
Martin Merinero H; Subías M; Pereda A; Gómez-Rubio E; Juana Lopez L; Fernandez C; Goicoechea de Jorge E; Martin-Santamaria S; Cañada FJ; Rodríguez de Córdoba S
Blood; 2021 Jun; 137(25):3484-3494. PubMed ID: 33651882
[TBL] [Abstract][Full Text] [Related]
4. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H.
Hellwage J; Jokiranta TS; Friese MA; Wolk TU; Kampen E; Zipfel PF; Meri S
J Immunol; 2002 Dec; 169(12):6935-44. PubMed ID: 12471127
[TBL] [Abstract][Full Text] [Related]
5. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein.
McRae JL; Duthy TG; Griggs KM; Ormsby RJ; Cowan PJ; Cromer BA; McKinstry WJ; Parker MW; Murphy BF; Gordon DL
J Immunol; 2005 May; 174(10):6250-6. PubMed ID: 15879123
[TBL] [Abstract][Full Text] [Related]
6. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
7. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.
Ferreira VP; Herbert AP; Cortés C; McKee KA; Blaum BS; Esswein ST; Uhrín D; Barlow PN; Pangburn MK; Kavanagh D
J Immunol; 2009 Jun; 182(11):7009-18. PubMed ID: 19454698
[TBL] [Abstract][Full Text] [Related]
8. Complement Factor H related protein 1 and immune inflammatory disorders.
Li X; Zong J; Si S
Mol Immunol; 2022 May; 145():43-49. PubMed ID: 35279539
[TBL] [Abstract][Full Text] [Related]
9. Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies.
Loeven MA; Maciej-Hulme ML; Yanginlar C; Hubers MC; Kellenbach E; de Graaf M; van Kuppevelt TH; Wetzels J; Rabelink TJ; Smith RJH; van der Vlag J
Front Immunol; 2021; 12():676662. PubMed ID: 34489931
[TBL] [Abstract][Full Text] [Related]
10. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
Pechtl IC; Kavanagh D; McIntosh N; Harris CL; Barlow PN
J Biol Chem; 2011 Apr; 286(13):11082-90. PubMed ID: 21270465
[TBL] [Abstract][Full Text] [Related]
11. Structural and functional characterization of the product of disease-related factor H gene conversion.
Herbert AP; Kavanagh D; Johansson C; Morgan HP; Blaum BS; Hannan JP; Barlow PN; Uhrín D
Biochemistry; 2012 Mar; 51(9):1874-84. PubMed ID: 22320225
[TBL] [Abstract][Full Text] [Related]
12. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for sialic acid-mediated self-recognition by complement factor H.
Blaum BS; Hannan JP; Herbert AP; Kavanagh D; Uhrín D; Stehle T
Nat Chem Biol; 2015 Jan; 11(1):77-82. PubMed ID: 25402769
[TBL] [Abstract][Full Text] [Related]
14. Biophysical analysis of sialic acid recognition by the complement regulator Factor H.
Schmidt CQ; Hipgrave Ederveen AL; Harder MJ; Wuhrer M; Stehle T; Blaum BS
Glycobiology; 2018 Oct; 28(10):765-773. PubMed ID: 29982679
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants.
Dekkers G; Brouwer MC; Jeremiasse J; Kamp A; Biggs RM; van Mierlo G; Lauder S; Katti S; Kuijpers TW; Rispens T; Jongerius I
J Immunol; 2020 Oct; 205(7):1778-1786. PubMed ID: 32848031
[TBL] [Abstract][Full Text] [Related]
16. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.
Lehtinen MJ; Rops AL; Isenman DE; van der Vlag J; Jokiranta TS
J Biol Chem; 2009 Jun; 284(23):15650-8. PubMed ID: 19351878
[TBL] [Abstract][Full Text] [Related]
17. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
Józsi M; Strobel S; Dahse HM; Liu WS; Hoyer PF; Oppermann M; Skerka C; Zipfel PF
Blood; 2007 Sep; 110(5):1516-8. PubMed ID: 17495132
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement.
Pangburn MK; Pangburn KL; Koistinen V; Meri S; Sharma AK
J Immunol; 2000 May; 164(9):4742-51. PubMed ID: 10779780
[TBL] [Abstract][Full Text] [Related]
19. Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome.
Goicoechea de Jorge E; Tortajada A; García SP; Gastoldi S; Merinero HM; García-Fernández J; Arjona E; Cao M; Remuzzi G; Noris M; Rodríguez de Córdoba S
J Am Soc Nephrol; 2018 Jan; 29(1):240-249. PubMed ID: 28993505
[TBL] [Abstract][Full Text] [Related]
20. FHR-1 Binds to C-Reactive Protein and Enhances Rather than Inhibits Complement Activation.
Csincsi ÁI; Szabó Z; Bánlaki Z; Uzonyi B; Cserhalmi M; Kárpáti É; Tortajada A; Caesar JJE; Prohászka Z; Jokiranta TS; Lea SM; Rodríguez de Córdoba S; Józsi M
J Immunol; 2017 Jul; 199(1):292-303. PubMed ID: 28533443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
